Actar
From Wikipedia, the free encyclopedia
 |
This article or section is written like an advertisement. Please help rewrite this article from a neutral point of view per Wikipedia policy. Mark blatant advertising for speedy deletion with {{db-spam}}. (help, talk) |
”From Academic Discovery to Pharmaceutical Development”
Despite the increased spending on research and development in the pharmaceutical industry, productivity is declining. Therefore the drug development process has been closely scrutinized for its value and cost. At the same time, important medicinal knowledge come out of publicly funded research at universities and institutes every year.
Actar was founded in year 2000 and is a biomedical company who builds the bridge from academic research that further pharmaceutical development needs by identifying, selecting and refining innovative biological targets. Actar substantially increases the value of each target by offering validated and complete licensing opportunities with substantial potential for pharmaceutical development.
If risk is reduced in early drug development process the prospects are fewer failures in clinical trials. Not only will the big pharmaceutical companies gain from this. With more medicinal innovations reaching the market we are also looking at benefits for public health in general.
[edit] References
Posner, Bruce A (2005). High-throughput screening-driven lead discovery: Meeting the challenges of finding new therapeutics Current Opinion in Drug Discovery & Development. Vol 8 No 4.
